Insufficient evidence regarding benefits from sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction

Abstract

Aim: Sodium-glucose cotransporter-2 (SGLT2)-inhibitors improve survival in adults with reduced ejection fraction. Clinical outcomes in adults with heart failure (HF) with preserved ejection fraction (HFpEF) have not been systematically reviewed.

Methods: We conducted a systematic rapid literature review and appraised the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation methodology.

Results: We identified post-hoc subgroup analyses of four randomized controlled clinical trials (RCTs) and unpublished results from 2 RCTs. In 2 RCTs vs. placebo, Canagliflozin reduced the risk of fatal or hospitalized HF in adults with HF and documented or assumed left ventricular ejection fraction (LVEF) ≥ 50% (hazard rate ratio, HR = 0.71, 95%CI: 0.52-0.97) but had no effect in a subpopulation with documented LVEF ≥ 50% (HR = 0.83, 95%CI: 0.55-1.25). Dapagliflozin or ertugliflozin did not improve all-cause or cardiovascular death or hospitalization for HF in adults with HF and LVEF > 45% in two pivotal RCTs vs. placebo. Empagliflozin did not improve exercise ability, patient-reported outcomes or congestion, diuretic use and all-cause healthcare resource utilization in unpublished RCT vs. placebo. Various definitions of HFpEF, post-hoc interaction analyses suggesting outcome improvement regardless of heart failure type, small number of events, and probable publication bias hampered the quality of evidence.

Conclusion: Existing evidence is insufficient to support definitive clinical recommendations for use of SGLT2- inhibitors in adults with HFpEF. Future research should employ consistent definitions of HFpEF and examine the effects from SGLT2- Inhibitors in patients with various HFpEF phenotypes and underlying causes.

Keywords

Sodium-glucose cotransporter-2 - inhibitors / heart failure with preserved ejection fraction / cardiovascular mortality / heart failure hospitalization / systematic literature review / grading of recommendations assessment / development and evaluation methodology

References

[1] Shamliyan T,Martin A.PCV63 what’s the cost of hospitalisations due to heart failure with preserved ejection fraction in the United States?.Value Health2019;22:S552-3

[2] Dhingra A,Kaur S.Epidemiology of heart failure with preserved ejection fraction..Curr Heart Fail Rep2014;11:354-65

[3] Ziaeian B,Xu H.Race/ethnic differences in outcomes among hospitalized medicare patients with heart failure and preserved ejection fraction..JACC Heart Fail2017;5:483-93 PMCID:PMC5524150

[4] Bouthoorn S,Gohar A.The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis..Diab Vasc Dis Res2018;15:477-93 PMCID:PMC6236645

[5] American Diabetes Association Position StatementCardiovascular disease and risk management: standards of medical care in diabetes-2020..Diabetes Care2020;43:S111-34

[6] American Diabetes Association Position Statement12. Older Adults: Standards of Medical Care in Diabetes-2020..Diabetes Care2020;43:S152-62

[7] Rawshani A,Franzen S.Mortality and cardiovascular disease in type 1 and type 2 diabetes..N Engl J Med2017;376:1407-18

[8] Htay T,Lopez-Perez A,Romagosa MA.Mortality and cardiovascular disease in type 1 and type 2 diabetes..Curr Cardiol Rep2019;21:45

[9] Borlaug BA.Evaluation and management of heart failure with preserved ejection fraction..Nat Rev Cardiol2020;17:559-73

[10] Oktay AA,Shah SJ.The emerging epidemic of heart failure with preserved ejection fraction..Curr Heart Fail Rep2013;10:401-10 PMCID:PMC3870014

[11] Zheng SL,Nabeebaccus AA.Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis..Heart (British Cardiac Society)2018;104:407-15 PMCID:PMC5861385

[12] Kjeldsen SE,Smiseth OA.Medical therapies for heart failure with preserved ejection fraction..Hypertension2020;75:23-32

[13] Gladden JD,Redfield MM.Heart failure with preserved ejection fraction..Ann Rev Med2018;69:65-79

[14] Bonsu KO,Chaiyakunapruk N.Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison..Heart Fail Rev2018;23:147-56

[15] Zelniker TA,Raz I.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials..Lancet (London, England)2019;393:31-9

[16] Birkeland KI,Carstensen B.Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis..Lancet Diabetes Endocrinol2017;5:709-17

[17] Zelniker TA.Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review..J Am Coll Cardiol2018;72:1845-55

[18] Singh AK.Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies..Expert Rev Clin Pharmacol2019;12:299-308

[19] Lan NSR,Yeap BB.The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions..ESC Heart Fail2019;6:927-35 PMCID:PMC6816235

[20] AstraZeneca Pharmaceuticals LP Wilmington D. FARXIGA- dapagliflozin tablet, film coated FDA label. May 2020. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/01f90c94-71cb-4a1f-81ff-8004b850529b/spl-doc?hl=dapagliflozin. [Last accessed on 16 Nov 2020]

[21] Boehringer Ingelheim Pharmaceuticals Inc. JARDIANCE- empagliflozin tablet, film coated FDA label. 2014. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/a77214ca-572e-485e-aae9-f7950187e5fb/spl-doc?hl=empagliflozin. [Last accessed on 16 Nov 2020]

[22] Janssen Pharmaceuticals Inc. INVOKANA- canagliflozin tablet, film coated FDA label. March 2013. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/b9057d3b-b104-4f09-8a61-c61ef9d4a3f3/spl-doc?hl=canagliflozin. [Last accessed on 16 Nov 2020]

[23] Fitchett D,Cannon CP.Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG outcome trial..Circulation2019;139:1384-95 PMCID:PMC6416009

[24] Radholm K,Perkovic V.Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program..Circulation2018;138:458-68 PMCID:PMC6075881

[25] Dewan P,Jhund PS.Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF..Eur J Heart Fail2020;22:1247-58

[26] Dunlay SM,Aguilar D.Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update..Circulation2019;140:e294-324

[27] Dunlay SM,Aguilar D.Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America..J Card Fail2019;25:584-619

[28] Ezekowitz JA,McDonald MA.2017 comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure..Can J Cardiol2017;33:1342-433

[29] O’Meara E,Chan M.CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis..Can J Cardiol2020;36:159-69

[30] Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. London: The Cochrane Collaboration; 2011. Available from: https://training.cochrane.org/handbook/current. [Last accessed on 16 Nov 2020]

[31] Slutsky J,Chang S.AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program..J Clin Epidemiol2010;63:481-3

[32] Polisena J,Kamel C,Abou-Setta AM.Rapid review programs to support health care and policy decision making: a descriptive analysis of processes and methods..Syst Rev2015;4:1-7 PMCID:PMC4407715

[33] Yancy CW.2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines..Circulation2013;128:e240-327

[34] Ponikowski P,Anker SD.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC..Eur Heart J2016;37:2129-200

[35] Chow B.The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis..Heart Fail Rev2015;20:291-303

[36] Machino-Ohtsuka T,Ishizu T.Clinical utility of the 2016 ASE/EACVI recommendations for the evaluation of left ventricular diastolic function in the stratification of post-discharge prognosis in patients with acute heart failure..Eur heart J Cardiovasc Imaging2019;20:1129-37

[37] Nagueh SF,Appleton CP.Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging..J Am Soc Echocardiogr2016;29:277-314

[38] Lindman BR,Mann DL.Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study..J Am Coll Cardiol2014;64:541-9 PMCID:PMC4133145

[39] Greene SJ,Fiuzat M.Reassessing the role of surrogate end points in drug development for heart failure..Circulation2018;138:1039-53 PMCID:PMC6205720

[40] Lekavich CL,Neelon V.Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review..Heart Fail Rev2015;20:643-53

[41] Zinman B,Lachin JM.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)..Cardiovasc Diabetol2014;13:102 PMCID:PMC4072621

[42] Wiviott SD,Bonaca MP.The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58 Trial..Am Heart J2018;200:83-9

[43] Ridderstrale M,Zeller C,Woerle HJ.Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control..Cardiovasc Diabetol2013;12:129 PMCID:PMC3844307

[44] Neal B,de Zeeuw D.Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial..Am Heart J2013;166:217-23.e11

[45] Abraham WT,Brueckmann M.Rationale and design of the EMPERIAL-preserved and EMPERIAL-reduced trials of empagliflozin in patients with chronic heart failure..Eur J Heart Fail2019;21:932-42 PMCID:PMC6774309

[46] Fu R,Grant M.Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program..J Clin Epidemiol2011;64:1187-97

[47] Levine M.Post hoc power analysis: an idea whose time has passed?.Pharmacotherapy2001;21:405-9

[48] Goodman SN.The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results..Ann Intern Med1994;121:200-6

[49] Yuan KH.On the post hoc power in testing mean differences..J Educ Behav Stat2005;30:141-67

[50] Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No 10(14)-EHC063-EF. 2014. Rockville, MD. Available from: https://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. [Last accessed on 16 Nov 2020]

[51] Guyatt GH,Kunz R.GRADE guidelines 6. Rating the quality of evidence--imprecision..J Clin Epidemiol2011;64:1283-93

[52] Viswanathan M,Dryden DM.Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank.2013;Rockville (MD)Agency for Healthcare Research and Quality (US)

[53] Higgins JP,Gotzsche PC.The cochrane collaboration’s tool for assessing risk of bias in randomised trials..BMJ2011;343:d5928 PMCID:PMC3196245

[54] Sterne JA,Reeves BC.ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions..BMJ2016;355: PMCID:PMC5062054

[55] Grading of Recommendations Assessment Development and Evaluation (GRADE) Workgin Group. GRADE Handbook. Available from: http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html#h.fueh5iz0cor4. [Last accessed on 16 Nov 2020]

[56] Guyatt GH,Sultan S.GRADE guidelines: 9. Rating up the quality of evidence..J Clin Epidemiol2011;64:1311-6

[57] Figtree GA,Barrett TD.Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus..Circulation2019;139:2591-3

[58] Kato ET,Mosenzon O.Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus..Circulation2019;139:2528-36

[59] Ponikowski P. Abraham W. Favourable effects of empagliflozin on congestion, diuretic use and all-cause healthcare resource utilisation in the EMPERIAL trials. European Society of Cardiology 365. 2020; HFA Discoveries. Available from: https://esc365.escardio.org/Congress/223730-favourable-effects-of-empagliflozin-on-congestion-diuretic-use-and-all-cause-healthcare-resource-utilisation-in-the-emperial-trials. [Last accessed on 16 Nov 2020]

[60] Lindenfeld J. Patient-reported outcomes with empagliflozin in the EMPERIAL trials. European Society of Cardiology 365. 2020; HFA Discoveries. Available from: https://esc365.escardio.org/Congress/223722-patient-reported-outcomes-with-empagliflozin-in-the-emperial-trials. [Last accessed on 16 Nov 2020]

[61] Boehringer Ingelheim. Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure. 2019. Available from: https://wwwboehringer-ingelheimus/press-release/boehringer-ingelheim-and-lilly-provide-update-jardiance-phase-iii-exercise-ability. [Last accessed on 16 Nov 2020]

[62] Cosentino F,Cherney DZI.Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial..Circulation2020;

[63] Mahaffey KW,Perkovic V.Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)..Circulation2018;137:323-34 PMCID:PMC5777572

[64] Matsutani D,Kayama Y,Horiuchi R.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes..Cardiovasc Diabetol2018;17:73 PMCID:PMC5963148

[65] Sezai A,Unosawa S,Osaka S.Canagliflozin for Japanese patients with chronic heart failure and type II diabetes..Cardiovasc Diabetol2019;18:76 PMCID:PMC6551875

[66] Singh JS, Fathi A, Vickneson K, et al. Research into the effect of sodium-glucose linked transporter inhibition in left ventricular remodelling in patients with heart failure and diabetes mellitus. Eur Heart J 2018;Supplement 1(P905): American Diabetes Association meeting, Orlando. Available from: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-1-Chronic-heart-failure-Treatment/177516-research-into-the-effect-of-sodium-glucose-linked-transporter-inhibition-in-left-ventricular-remodelling-in-patients-with-heart-failure-and-diabetes-mellitus. [Last accessed on 16 Nov 2020]

[67] Bonora BM,Avogaro A.Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial..Cardiovasc Diabetol2019;18:106 PMCID:PMC6694690

[68] Verma S,Yan AT.Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG outcome trial?.Diabetes Care2016;39:e212-3

[69] Cannon CP,Pratley R.Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety cardiovascular outcomes trial (VERTIS-CV)..Am Heart J2018;206:11-23

[70] Cannon CP,Dagogo-Jack S.Cardiovascular outcomes with ertugliflozin in type 2 diabetes..New Engl J Med2020;383:1425-35

[71] Sakai T, Miura S. Abstract 17041: effect of sodium-glucose cotransporter 2 inhibitor on vascular endothelial function and diastolic function in patients with heart failure with preserved ejection fraction (hfpef). Circulation 2017;136:A17041. Available from: https://www.ahajournals.org/doi/10.1161/circ.136.suppl_1.17041. [Last accessed on 16 Nov 2020]

[72] Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, et al. Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection fraction in diabetic patients: a multicenter randomized-controlled trial. ESC Congress 2019. Available from: https://esc365.escardio.org/Congress/ESC-CONGRESS-2019/New-treatment-studies-in-heart-failure/196088-drug-effect-of-luseogliflozin-and-voglibose-on-heart-failure-with-preserved-ejection-fraction-in-diabetic-patients-a-multicenter-randomized-controlled-trial#abstract(Abstract: 1407). [Last accessed on 16 Nov 2020]

[73] U.S. Food and Drug Administration. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. Postmarket Drug Safety Information for Patients and Providers 2020. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/sodium-glucose-cotransporter-2-sglt2-inhibitors. [Last accessed on 16 Nov 2020]

[74] Ida S,Imataka K.Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis..Heart Fail Rev2020;

[75] Zhang DP,Wang LF,Jiang F.Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis..Cardiovasc Diabetol2020;19:10 PMCID:PMC6977298

[76] White RD,Bolen MA,Brown RKJ.ACR Appropriateness Criteria((R)) Suspected New-Onset and Known Nonacute Heart Failure..J Am Coll Radiol2018;15:S418-31

[77] Pieske B,de Boer RA.How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)..Eur heart J2019;40:3297-317

[78] Reddy YNV,Obokata M,Borlaug BA.A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction..Circulation2018;138:861-70 PMCID:PMC6202181

[79] Reddy YNV.Response by reddy and borlaug to letters regarding article, “a simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction”..Circulation2019;139:992-3 PMCID:PMC6373473

[80] Obokata M,Borlaug BA.Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods..JACC Cardiovasc Imaging2020;13:245-57 PMCID:PMC6899218

[81] Wittbrodt ET,Bell KF,Latham K.Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population..Am J Manag Care2018;24:S138-45

[82] Chetrit M,Klein AL.Imaging of diastolic dysfunction in community-based epidemiological studies and randomized controlled trials of HFpEF..JACC Cardiovasc Imaging2020;13:310-26

[83] Ho JE,Wooster L.Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions..Circulation2019;140:353-65 PMCID:PMC6684250

[84] Oh JK,Bird JG,Nagueh SF.The 2016 diastolic function guideline: is it already time to revisit or revise them?.JACC Cardiovasc Imaging2020;13:327-35

[85] van der Meer P,Dec GW.ACC/AHA versus ESC Guidelines on Heart Failure: JACC Guideline Comparison..J Am Coll Cardiol2019;73:2756-68

[86] Wallach JD,Trepanowski JF,Steyerberg EW.Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials..JAMA Int Med2017;177:554-60 PMCID:PMC6657347

[87] Brookes ST,Peters TJ,Egger M.Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives..Health Technol Assess2001;5:1-56

[88] Yancy CW,Bozkurt B.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America..J Cardiac Fail2017;23:628-51

[89] Das SR,Birtcher KK.2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the american college of cardiology solution set oversight committee..J Am Coll Cardiol2020;76:1117-45 PMCID:PMC7545583

[90] Seferovic PM,Ponikowski P.European society of cardiology/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure..Eur J Heart Fail2020;22:196-213

[91] Yancy CW.2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America..Circulation2016;134:e282-93

[92] Gunawan F,Partridge C,Kosiborod M.Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications..Cardiovasc Endocrinol Metab2020;9:56-9 PMCID:PMC7228775

[93] Zoler ML. SGLT2 Inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists. MedScape. 2020; Medscape Medical News: Conference News: ADA 2020. Available from: https://www.medscape.com/viewarticle/934107. [Last accessed on 16 Nov 2020]

[94] American Diabetes Association Position Statement 10Cardiovascular disease and risk management: standards of medical care in diabetes - 2020..Diabetes Care2020;43:S111-34

[95] American Diabetes Association Position Statement 4Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes - 2020..Diabetes Care2020;43:S37-47

[96] Neumann PJ,Jonsson B,Schwartz JS.Are key principles for improved health technology assessment supported and used by health technology assessment organizations?.Int J Technol Assess Health Care2010;26:71-8

[97] Kristensen FB,Chase DL.Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA..Int J Technol Assess Health Care2009;25:1-8

[98] World Health Organization. 2015 Global Survey on Health Technology Assessment by National Authorities. ISBN 978 92 4 150974 9. 2015. Available from: https://www.who.int/health-technology-assessment/MD_HTA_oct2015_final_web2.pdf?ua=1. [Last accessed on 16 Nov 2020]

[99] Fanourgiakis J.Health technology assessment (HTA): a brief introduction of history and the current status in the field of cardiology under the economic crisis..J Evid Based Med2015;8:161-4

[100] Elbarbary M.Health technology assessment (HTA) in cardiac field..J Saudi Heart Assoc2010;22:77-84 PMCID:PMC3727464

[101] The International Network of Agencies for Health Technology Assessment. The Uniquiness of INAHTA INAHTA Position Statement. 2020. Available from: https://www.inahta.org/position-statements/. [Last accessed on 16 Nov 2020]

[102] Yaku H,Morimoto T.Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan- observations from the prospective, multicenter kyoto congestive heart failure (KCHF) registry..Circ J2018;82:2811-9

[103] Parissis J,Triposkiadis F.Heart failure registries: how far can we go?.Euro J Heart Fail2016;18:626-8

[104] Bassand JP,Atar D.GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke..Future Cardiol2020;

[105] Alhabib KF,Almahmeed W.Acute myocardial infarction and acute heart failure in the Middle East and North Africa: study design and pilot phase study results from the PEACE MENA registry..PLoS One2020;15:e0236292 PMCID:PMC7375595